Like water spewing from a firehose, venture dollars are dousing life-science startups this week. The latest biotech on the receiving end is Rubius Therapeutics, a cell therapy developer that announced a $100 million round this morning.
With the new cash, a “crossover” round including investors that back both private and publicly traded companies, Rubius has now raised $220 million from founding backer Flagship Pioneering and others in nine months. Rubius president Torben Straight Nissen said the company is funded by institutional biotech investors and “some of the largest mutual funds in the world,” but wouldn’t provide specifics.
The cash and… Read more »
UNDERWRITERS AND PARTNERS